title: Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival.
abstract: BACKGROUND
  Triple-negative breast cancer (TNBC) has the highest mortality rates of all subtypes. Anthracycline and taxane regimens yield unsatisfactorily low rates of pathologic complete response (pCR) and are often not feasible in cardiac comorbidity. This study seeks to increase pCR and survival by introducing platin agents.
  
  
  METHODS
  In this multicentric, open-label study with six cycles of docetaxel (75 mg/m(2)) and carboplatin AUC 6 q3w, patients were unwilling or unsuitable for anthracycline-based regimens. Primary endpoint was pCR (ypT0/ypTis ypN0) and survival.
  
  
  RESULTS
  pCR rate was 50%. After 2 and 5 years, overall survival (OS) was 96.7 and 89.7%, disease-free-survival (DFS) 96.7 and 85.7%, DDFS 96.7 and 89.6%. Grade 3/4 toxicities were rare. Ninety-three per cent of patients completed six cycles. No toxicity-related treatment discontinuation or febrile neutropaenia was recorded.
  
  
  CONCLUSIONS
  This regimen is highly effective and feasible in TNBC and may be combined with anthracyclines.
authors.affiliation: a Universitat Duisburg-Essen, University Hospital of Essen, Women's Department , Düsseldorf , Germany.|b GBG Forschungs GmbH, German Breast Group , Neu-Isenburg , Germany.
authors.forename: Peter
authors.initials: P
authors.lastname: Kern
authors.affiliation: a Universitat Duisburg-Essen, University Hospital of Essen, Women's Department , Düsseldorf , Germany.
authors.forename: Anne
authors.initials: A
authors.lastname: Kalisch
authors.affiliation: b GBG Forschungs GmbH, German Breast Group , Neu-Isenburg , Germany.
authors.forename: Gunter
authors.initials: G
authors.lastname: von Minckwitz
authors.affiliation: c Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), Universitat Duisburg-Essen , Germany.
authors.forename: Carolin
authors.initials: C
authors.lastname: Pütter
authors.affiliation: d Marienhospital Bottrop, Women's Department , Germany.
authors.forename: Hans-Christian
authors.initials: HC
authors.lastname: Kolberg
authors.affiliation: e Clinic of Hematology and Oncology , Bottrop , Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Pott
authors.affiliation: f Medical Center Bonn Friedensplatz , Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Kurbacher
authors.affiliation: g European Breast Center Düsseldorf, Luisen Hospital , Germany.
authors.forename: Mahdi
authors.initials: M
authors.lastname: Rezai
authors.affiliation: a Universitat Duisburg-Essen, University Hospital of Essen, Women's Department , Düsseldorf , Germany.
authors.forename: Rainer
authors.initials: R
authors.lastname: Kimmig
mesh_terms: D000328:Adult; D000368:Aged; D018943:Anthracyclines; D000971:Antineoplastic Combined Chemotherapy Protocols; D016190:Carboplatin / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant / Q000379:methods; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D009367:Neoplasm Staging; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage*; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology
chemical_list: D018943:Anthracyclines; D043823:Taxoids; D000077143:Docetaxel; D016190:Carboplatin
keywords: Anthracycline-free; Carboplatin; Docetaxel; Pathological complete response; Survival; Triple-negative breast cancer